Trial Profile
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Alveolar soft part sarcoma; Brain metastases
- Focus Therapeutic Use
- 15 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 22 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 11 Mar 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.